Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea‐induced hypoglycaemia: A GoDARTS Study. Issue 1 (25th August 2017)

• Record Type: Journal Article
• Authors: Dujic, Tanja; Zhou, Kaixin; Donnelly, Louise A.; Leese, Graham; Palmer, Colin N. A.; Pearson, Ewan R.
• Is Part Of: Diabetes, obesity & metabolism. Volume 20:Issue 1(2018)
• Page Start: 211
• Page End: 214
• Publication Date: 2017-08-25
• Subjects: hypoglycaemia -- pharmacogenetics -- sulphonylureas -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13046
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : Data on the association of CYP2C9 genetic polymorphisms with sulfonylurea (SU)‐induced hypoglycaemia (SH) are inconsistent. Recent studies showed that variants in the P450 oxidoreductase (POR) gene could affect CYP2C9 activity. In this study, we explored the effects of POR*28 and combined CYP2C9*2 and CYP2C9*3 genotypes on SH and the efficacy of SU treatment in type 2 diabetes. A total of 1770 patients were included in the analysis of SU efficacy, assessed as the combined outcome of the HbA1c reduction and the prescribed SU daily dose. Sixty‐nine patients with severe SH were compared with 311 control patients. The number of CYP2C9 deficient alleles was associated with nearly three‐fold higher odds of hypoglycaemia (OR, 2.81; 95% CI, 1.30‐6.09; P = .009) and better response to SU treatment (β, −0.218; SE, 0.074; P = .003) only in patients carrying the POR*1/*1 genotype. Our results indicate that interaction between CYP2C9 and POR genes may be an important determinant of efficacy and severe adverse effects of SU treatment.